RARA and myelodysplastic syndrome: reported that HMA‐induced endogenous retroviruses could selectively kill p53‐mutant MEF cells.[3] Similar p53 mutant‐preferential antileukemic activity of decitabine, in combination with ATRA in AML upon PML/RARA‐negative AML blasts, was reported in vitro and in vivo.[30, 46] The effect of HMA in selectively benefiting p53‐mutant AML/MDS patients are also reported in the clinics.